Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.44 |
| ▸ | VNN1 | O95497 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13608070 | 0.88 | IRAK1 (0.43) | GRIN2BADORA3 | |
| SCHEMBL3852615 | 0.87 | PRKCQ (0.53) | — | |
| SCHEMBL3845823 | 0.83 | PRKCQ (0.41) | GRIN2BVNN1 | |
| SCHEMBL3852089 | 0.79 | PRKCQ (0.42) | GRIN2BVNN1CDK1CDK2NTRK1 | |
| SCHEMBL3844922 | 0.77 | GRIN2B (0.41) | GRIN2BADORA3VNN1 | |
| SCHEMBL13608069 | 0.76 | PRKCQ (0.50) | — | |
| SCHEMBL19665574 | 0.75 | MAPK8 (0.40) | GRIN2BADORA3 | |
| SCHEMBL3849773 | 0.74 | PRKCQ (0.41) | — | |
| SCHEMBL3851085 | 0.73 | PRKCQ (0.39) | GRIN2BCDK2 | |
| SCHEMBL13608085 | 0.73 | SYK (0.44) | GRIN2BCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009062059-A2 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | GRIN2B 953/4885ADORA3 1135/4885VNN1 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.